Year All202520242023202220212020201920182017 Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions Oct 10, 2023 Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting Oct 06, 2023 Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) Sep 26, 2023 Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023 Sep 20, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 06, 2023 Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 05, 2023 Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Aug 08, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2023 Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock Aug 01, 2023 Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock Jul 27, 2023
Year All202520242023202220212020201920182017 Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions Oct 10, 2023 Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting Oct 06, 2023 Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) Sep 26, 2023 Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023 Sep 20, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 06, 2023 Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 05, 2023 Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Aug 08, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2023 Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock Aug 01, 2023 Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock Jul 27, 2023
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions Oct 10, 2023
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting Oct 06, 2023
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) Sep 26, 2023
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 05, 2023
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Aug 08, 2023